Biogen 30-Day Option Volume & Interest Snapshot Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today ...
Some results have been hidden because they may be inaccessible to you